ليتروزول تيڤع

Pays: Israël

Langue: arabe

Source: Ministry of Health

Ingrédients actifs:

LETROZOLE 2.5 MG

Disponible depuis:

TEVA PHARMACEUTICAL INDUST.LTD

Code ATC:

L02BG04

forme pharmaceutique:

TABLETS

Mode d'administration:

PER OS

Fabriqué par:

TEVA PHARMACEUTICAL INDUSTRIES LTD

Groupe thérapeutique:

LETROZOLE

indications thérapeutiques:

Letrozole teva tablets is indicated for first-line treatment in postmenopausal women with hormone receptor positive or in whom hormone receptor status cannot be determined, locally advanced or metastatic breast cancer: Letrozole teva is also indicated for the treatment of advanced breast cancer in postmenopausal women with disease progression following antiestrogen therapy. Extended adjuvant treatment of early breast cancer in post menopausal women who have received prior standard adjuvant tamoxifen therapy. Adjuvant treatment of postmenopausal women with hormone receptor positive early breast cancer.

Date de l'autorisation:

2010-01-01